 | | Vol. 14.07 – 24 February, 2023 |
| |
|
|
| Investigators adopted an in vitro spheroid invasion screening assay to prostate cancer cells expressing KLF5K369Q, a mutant mimicking Ac-KLF5.
[BMC Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists identified potential biomarkers for prostate cancer progression and metastasis, as well as discerned their biological functions.
[Cell & Bioscience] |
|
|
|
| Within a series of novel L-Phenylalanin dipeptides designed, a particular compound exhibited potent antitumor activity against prostate cancer cell PC3 in vitro and in vivo via inducing apoptosis.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Investigators found that lincROR was highly expressed in docetaxel-resistant prostate cancer (PCa) cell lines, and was associated with poor docetaxel response in metastatic PCa patients.
[Molecular Cancer Research] |
|
|
|
| Scientists used immunofluorescence and transmission electron microscopy to quantify and characterize the ultrastructural interactions between platelets and two prostate cancer cell lines, MDA PCa 2b and RC77 T/E.
[Scientific Reports] |
|
|
|
| To identify cell surface proteins potentially identifying quiescent prostate cancer cells for future patient samples or for antibody-based therapeutic research, researchers focused on differentially abundant plasma membrane proteins and identified HER2 as a cell surface protein enriched on G0 prostate cancer cells.
[Translational Oncology] |
|
|
|
| Scientists investigated the influence of umbilical cord-mesenchymal stromal/stem cell secretome and cord blood serum on two human prostate cancer cell lines and a normal epithelial prostate cell line.
[Human Cell] |
|
|
|
| Researchers evaluated a role for human single-strand binding protein 1 (hSSB1/NABP2) in modulation of the cellular response to androgens and ionizing radiation.
[The Prostate] |
|
|
|
| Scientists identified and clinically validated multiple genes being linked with the progression of prostate cancer and proposed several novel risk genes.
[PLOS One] |
|
|
|
|
| The authors provide new insight for reversing drug resistance in prostate cancer.
[Biomedicine & Pharmacotherapy] |
|
|
|
| Investigators discuss the efficacy and safety of second-generation androgen receptor inhibitors and propose that for patients with nonmetastatic castration-resistant prostate cancer, safety considerations for these treatments are especially important.
[Future Oncology] |
|
|
|
| The authors summarize the functional roles of ubiquitin-specific proteases in the development of prostate cancer and explored their potential applications as therapeutic targets for prostate cancer.
[Peerj Life & Environment] |
|
|
|
|
| BioAtla, Inc. announced that the US FDA had cleared its investigation new drug application to evaluate BA3182 for the treatment of advanced adenocarcinoma. BioAtla planned to initiate and advance a Phase I dose-escalation and expansion clinical study in 2023.
[BioAtla, Inc.] |
|
|
|
|
| March 5 – 9, 2023
Banff, Alberta, Canada |
|
|
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | The Henry Ford Health System – Detroit, Michigan, United States |
|
|
|
| | Vancouver Prostate Centre – Vancouver, British Columbia, Canada |
|
|
|
| | Dana-Farber Cancer Institute – Boston, Massachusetts, United States |
|
|
|
| | University of Rochester Medical Center – Rochester, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
